An official website of the United States government
The .gov means it's official. Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you're on a federal government site.
The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.
skin in Mus musculus (2)All 2 Gene records
Clinical Review Report: Dupilumab (Dupixent): (Sanofi Genzyme, a division of sanofi-aventis Canada Inc.): Indication: Indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Jun.
Top results in this bookTable of Contents
Clinical Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild to moderate atopic dermatitis in patients 2 years of age and older [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr.
Clinical Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2018 Jul.
Pharmacoeconomic Review Report: Crisaborole Ointment, 2% (Eucrisa): (Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Pharmacoeconomic Review Report: Dupilumab (Dupixent): (Sanofi-Aventis Canada Inc.): Indication: Moderate-to-severe atopic dermatitis (AD) [Internet].
Topical Antibiotics for Infected Dermatitis: A Review of the Clinical Effectiveness and Guidelines [Internet].
Tran K, Wright MD.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2017 Mar 3.
Pharmacoeconomic Report: Dupilumab (Dupixent): (Sanofi Genzyme, a division of sanofi-aventis Canada Inc.): Indication: Indicated for the treatment of patients aged 12 years and older with moderate-to-severe atopic dermatitis whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable [Internet].
Emollient Treatments for Atopic Dermatitis: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet].
Pohar R, McCormack S.
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Jan 14.
CADTH Canadian Drug Expert Committee Recommendation: Dupilumab (Dupixent — Sanofi-Aventis Canada Inc.): Indication: Atopic dermatitis [Internet].
Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2020 Apr 24.
StatPearls [Internet].
Treasure Island (FL): StatPearls Publishing; 2024 Jan-.
CADTH Canadian Drug Expert Committee Recommendation: Crisaborole (Eucrisa — Pfizer Canada Inc.): Indication: For topical treatment of mild-to-moderate atopic dermatitis in patients two years of age and older [Internet].
Itch: Mechanisms and Treatment.
Carstens E, Akiyama T, editors.
Boca Raton (FL): CRC Press/Taylor & Francis; 2014.
Systematic review of treatments for atopic eczema.
Hoare C, Li Wan Po A, Williams H.
Southampton (UK): NIHR Journals Library; 2000 Dec. (Health Technology Assessment, No. 04.37.)
Scoping systematic review of treatments for eczema.
Nankervis H, Thomas KS, Delamere FM, et al.
Southampton (UK): NIHR Journals Library; 2016 May. (Programme Grants for Applied Research, No. 4.7.)
Maternal Diet during Pregnancy and Lactation and Risk of Child Food Allergies and Atopic Allergic Diseases: A Systematic Review [Internet].
Donovan S, Dewey K, Novotny R, et al.
Alexandria (VA): USDA Nutrition Evidence Systematic Review; 2020 Jul.
Toxicological Profile for Formaldehyde.
Atlanta (GA): Agency for Toxic Substances and Disease Registry (US); 1999 Jul.
GeneReviews® [Internet].
Adam MP, Feldman J, Mirzaa GM, et al., editors.
Seattle (WA): University of Washington, Seattle; 1993-2024.
Clinical Methods: The History, Physical, and Laboratory Examinations. 3rd edition.
Walker HK, Hall WD, Hurst JW, editors.
Boston: Butterworths; 1990.
Infectious Diseases of Mice and Rats.
National Research Council (US) Committee on Infectious Diseases of Mice and Rats.
Washington (DC): National Academies Press (US); 1991.
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on